Geron Corporation (NASDAQ:GERN)
Industry: Healthcare

Geron Corporation operates as a biopharmaceutical company. The company supports the clinical stage development of a telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California.

Current Quote*
Last: $1.980
Change: -0.010
Book: $4.000
Volume: 2,960,187

As Of: 12/15 16:35 ET
*Quotes delayed by 20min.

Graphs for GERN


3 Month Graph


6 Month Graph


1 Year Graph